Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Kindred Biosciences, Inc. (KIN)
|
Add to portfolio |
|
|
|
| Price: |
$4.93
| | Metrics |
| OS: |
45.5
|
M
| |
|
|
| Market cap: |
$224
|
M
| |
|
|
|
Net cash:
|
$34.6
|
M
| |
$0.76
|
per share
|
|
EV:
|
$190
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| Revenues | 42.2 | 4.3 | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 890.7% | 116.5% | | | | | | -100.0% |
| Cost of goods sold | 4.6 | 0.6 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 37.5 | 3.7 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 89.0% | 86.2% | 83.5% | | | | | |
| Research and development | 31.3 | 28.3 | 26.4 | 17.7 | 13.9 | 19.4 | 18.7 | 3.1 |
| General and administrative | 22.0 | 37.9 | 26.5 | 14.0 | 8.3 | 7.9 | 8.5 | 1.1 |
| EBIT | -15.7 | -62.6 | -51.3 | -31.7 | -22.2 | -27.3 | -27.2 | -4.2 |
| EBIT margin | -37.3% | -1470.1% | -2607.1% | | | | | |
| Pre-tax income | -21.8 | -61.4 | -49.7 | -30.9 | -22.5 | -27.1 | -27.1 | -4.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -21.8 | -61.4 | -49.7 | -30.9 | -22.5 | -27.1 | -27.1 | -4.2 |
| Net margin | -51.7% | -1442.4% | -2527.5% | | | | | |
| |
| Diluted EPS | ($0.55) | ($1.59) | ($1.60) | ($1.23) | ($1.13) | ($1.37) | ($1.44) | ($1.13) |
| Shares outstanding (diluted) | 39.3 | 38.7 | 31.0 | 25.1 | 19.9 | 19.8 | 18.8 | 3.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|